Skip to content

Ketamine: all studies

Page 170 of 448: studies 1,691 to 1,700 of 4,475, newest first. Back to the ketamine overview

Research

Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.

Journal of Affective Disorders April 1, 2023 Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, Jacqueline Khalil et al. 16 citations

INTRODUCTION Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD). We performed an exploratory investigation of how ketamine treatment in TRD affects different cognitive domains and relates to antidepressant response. METHODS Patients with TRD (N = 66; 30 M/35F; age = 39.5 ± 11.1 years) received four ketamine infusions (0.5 mg/kg). Neurocognitive...

Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine.

Psychopharmacology April 1, 2023 David S. Mathai, Sandeep M. Nayak, David B. Yaden et al. 36 citations

The relationship between subjective drug experience and antidepressant outcomes for ketamine derivatives is poorly understood but of high clinical relevance. Esketamine is the patented (S)-enantiomer of ketamine and has regulatory approval for psychiatric applications. We examined the relationship between acute dissociation, as measured by the Clinician-Administered Dissociative States Scale...

Prenatal ketamine exposure impairs prepulse inhibition via arginine vasopressin receptor 1A-mediated GABAergic neuronal dysfunction in the striatum.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie April 1, 2023 Aeseul Kim, Sun Mi Gu, Haemiru Lee et al. 5 citations

Ketamine is a widely used anesthetic with N-methyl-D-aspartate (NMDA) receptor antagonism. Exposure to ketamine and NMDA receptor antagonists may induce psychosis. However, the mechanism underlying the effects of ketamine on the immature brain remains unclear. In this study, NMDA receptor antagonists, ketamine and methoxetamine, were administered to pregnant F344 rats (E17). These regimens...

DOI: 10.1016/j.biopha.2023.114318 (opens in new tab) Full text (opens in new tab) Methoxetamine N-methyl-d-aspartate receptor Prepulse inhibition Δ-aminobutyric acid

The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics.

Neurochemical Research April 1, 2023 Jared VanderZwaag, Torin Halvorson, Kira Dolhan et al. 25 citations

There is much excitement surrounding recent research of promising, mechanistically novel psychotherapeutics - psychedelic, anesthetic, and dissociative agents - as they have demonstrated surprising efficacy in treating central nervous system (CNS) disorders, such as mood disorders and addiction. However, the mechanisms by which these drugs provide such profound psychological benefits are still...

Efficacy of Electroconvulsive Therapy and Ketamine Therapy in Major Depressive Disorder; A Comparative Study

Pakistan Armed Forces Medical Journal March 30, 2023 Asif Azeem Bajwa, Sohail Ali, Sikandar Ali Khan et al. 1 citation

Objective: To evaluate and compare the efficacy of Electroconvulsive therapy (ECT) and Ketamine infusions in hospitalized patients suffering from major depressive disorder (MDD). Study Design: Comparative cross-sectional study. Place and duration of study: Armed Forces Institute of Mental Health, Rawalpindi Pakistan, from Feb to Apr 2021. Methodology: Forty in-patients diagnosed as having MDD...

Characterizing brain dynamics during ketamine-induced dissociation and subsequent interactions with propofol using human intracranial neurophysiology

Nature Communications March 29, 2023 Fangyun Tian, Laura D. Lewis, David W. Zhou et al. 63 citations

The neural mechanisms underpinning ketamine’s dissociative and antidepressant effects remain poorly understood. Here, the authors analyzed ketamine-induced brain dynamics with intracranial recordings in humans and found that ketamine engages different brain areas in distinct frequency-dependent patterns that may relate to its dissociative and antidepressant effects. Ketamine produces...

Ketamine for Treatment‐Resistant bipolar depression—A reality check!

Bipolar Disorders March 28, 2023 Balwinder Singh

Ketamine is a novel drug used for treatment- resistant depression. The initial randomized controlled trials (RCTs) established intravenous (IV) ketamine's rapid antidepressant effects for refrac-tory major depression, leading to its widespread use. However, the data for ketamine's efficacy in treatment- resistant bipolar depression (TRBD) remain minimal. There are 3 single infusion RCTs ( n =...

Esketamine ameliorates post-stroke anxiety by modulating microglial HDAC3/NF-κB/COX1 inflammatory signaling in ischemic cortex.

European Journal of Pharmacology March 28, 2023 Ailing Huang, Yang Chen, Shaoshuang Wang et al.

Post-stroke anxiety (PSA) is a kind of affective disorder occurring after a stroke, with anxiety as the primary clinical manifestation. PSA's mechanism is unclear, and there are few prevention and treatment measures. Our previous study found that HDAC3 could activate NF-κB signaling through mediated p65 deacetylation, which further influenced microglia activation. That implies HDAC3 may be the...

DOI: 10.1016/j.ejphar.2023.175667 (opens in new tab) Esketamine Microglia Animals Mice, inbred c57bl +6

Ketamine Evolving Clinical Roles and Potential Effects with Cognitive, Motor and Driving Ability

Neurology International March 28, 2023 Amber N. Edinoff, Saveen Sall, Colby B. Koontz et al. 5 citations

While driving under the influence of drugs, drivers are more likely to be involved in and cause more accidents than drivers who do not drive under the influence. Ketamine is derived from phencyclidine and acts as a noncompetitive antagonist and allosteric modulator of N-methyl-D-aspartate receptors. Ketamine has been used to treat a variety of psychiatric disorders, with the most notable being...

A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation

The International Journal of Neuropsychopharmacology March 26, 2023 T. Su, Cheng-Ta Li, Wei-Chen Lin et al. 48 citations

Abstract Background The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation. The effects of treatment refractoriness, the duration of the current depressive episode, and the number of prior antidepressant failures on ketamine efficacy also require clarification. Methods We recruited 84 outpatients...